Use of non-invasive imaging technologies to monitor in vivo gene-expression

• US 20030053951A1
• Filed: 07/26/2002
• Published: 03/20/2003
• Est. Priority Date: 07/26/2001
• Status: Abandoned Application

• Current Assignee: Gene Logic, Inc. (Steel Partners Holdings LP)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Tartaglia, Louis A., Stricker-Krongrad, Alain
• Application Number:
  US10/206,893
• Publication Number:
  US 20030053951A1
• Time in Patent Office: Days
• US Class Current: 424/9.2
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: C12Q 2525/143 incorporating a promoter sequence
• CPC Class Codes: C12Q 2565/628 being a surface plasmon resonance spectrometer

Abstract

The present invention provides methods of using non-invasive imaging technologies to monitor the effects of potential therapeutic compounds on gene expression in non-human living animals. This invention also provides methods to analyze perturbation in biochemical pathways and physiological functions associated with disease (e.g. a cancer, cardiovascular disease, degenerative nervous system disease, osteoporosis, disease related to body weight regulation, toxicity, and any other disease condition related to abnormal gene expression) using the non-invasive imaging technologies to monitor alterations in gene expression in non-human living animals.

Claims

1. A method of monitoring the effect of a compound on target gene expression in an animal, the method comprising:

(a) providing an animal expressing a reporter gene operably linked to expression control elements associated with a target gene;

(b) administering a test compound to the animal; and

(c) non-invasively detecting a shift in resonance in the presence of the reporter gene product as being indicative of an increase or decrease in the target gene expression in the presence of the test compound.

3. The method of claim 1 or 2, wherein the target gene is operably linked to a reporter gene.

4. The method of claim 1 or 2, wherein the target gene is replaced by a reporter gene

5. The method of claim 4, wherein the reporter gene is expressed in a tissue-specific manner.

6. The method of claim 4, wherein the reporter gene is ubiquitously expressed in all tissues.

7. The method of claim 1 or 2, wherein the reporter gene is placed in the genome at the site of an endogenous target gene.

8. The method of claim 1 or 2, wherein the reporter gene is randomly integrated into the genome of the animal.

9. The method of claim 1 or 2, wherein the target gene product is a component of a signal transduction pathway.

10. The method of claim 9, wherein the target gene product is a component of a pathway selected from the group consisting of a G-protein coupled receptor pathway.

11. The method of claim 9, wherein the target gene product is a component of the adenylyl cyclase pathway.

12. The method of claim 9 wherein the target gene product is a component of a ligand-stimulated receptor pathway.

13. The method of claim 9, wherein the target gene is a component of the phospholipase C pathway.

14. The method of claim 9, wherein the target gene is a member a intracellular signaling pathway.

15. The method of claim 9, wherein the target gene product is a G protein.

16. The method of claim 9, where the target gene contains a domain selected from the group consisting of SH2, PTB, SH3, WW, FHA, SAM, LIM, PX, EH, EVH1 and PDZ.

17. The method of claim 9, wherein the target gene product is c-fos.

18. The method of claim 9, wherein the target gene product is NFAT.

19. The method of claim 9, wherein the target gene product is cAMP response element.

20. The method of claim 1 or 2, wherein the reporter gene is selected from a group consisting of:

a LacZ reporter gene, a lux reporter gene, and a luc reporter gene.

21. The method of claim 1 or 2, wherein the reporter gene product metabolizes a substrate such that the substrate undergoes a resonance shift.

22. The method of claim 1 or 2, wherein the reporter gene encodes a protein comprising a fluorescent acceptor moiety.

23. The method claim 1 or 2, wherein the animal is selected from a group consisting of:

a transgenic animal, a knockout animal;

a knockin animal; and

an animal that expresses recombination activating gene (RAG).

24. The method of claim 1 or 2, wherein the effect of the test compound on target gene expression is monitored during normal developmental stages.

25. The method claim 1 or 2, wherein the effect of the test compound on target gene expression is determined in an animal model for a disease selected from the group consisting of:

a cancer, a cardiovascular disease, degenerative nervous system disease, osteoporosis, a disease related to body weight regulation, and a disease condition resulting from abnormal gene expression.

27. The method of claim 1, wherein the shift in resonance is measured by magnetic resonance imaging;

a high resolution positron emission technology for small animal imaging;

computerized tomography;

or single photon emission computed tomography.

2. A method of monitoring the effect of a compound on target gene expression in an animal, the method comprising:

(a) providing an animal expressing a reporter gene operably linked to expression control elements associated with the target gene;

(b) administering a test compound to the animal;

(c) administering a recorder substrate to the animal;

(d) non-invasively detecting a shift in resonance of the recorder substrate as being indicative of an increase or decrease in the target gene expression in the presence of the test compound.

26. The method claim 2, wherein the said recorder substrate is selected from a group consisting of:

a gadolinium chelated sugar moiety, a fluorine labeled enzyme substrate, a phosphorous labeled enzyme substrate, a carbon labeled enzyme substrate, a boron labeled enzyme substrate, and a substrate that undergoes a resonance shift upon cleavage.

28. The method claim 2, wherein the recorder substrate is measured by a magnetic resonance imaging;

a high resolution positron emission technology for small animal imaging;

computerized tomography;

or single photon emission computed tomography.

29. A noninvasive method for detecting a level of gene expression in response to a compound, wherein said expression is regulated by alterations in cellular physiology, said method comprising:

(a) administering the compound to a transgenic animal under conditions that permit proton generation mediated by a proton generating compound associated with the gene product

(b) placing the animal within a detection field of a proton detector device,

(c) maintaining the animal in the detection field of the device, and

(d) d measuring the proton emission in the animal with the proton detector device to detect the level of the proton generating compound the associated with a gene product whose expression regulated by alterations in cellular physiology, wherein an increase or decrease in the level of the proton generating compound is indicative of an alteration in gene expression in the presence of the compound.

30. The method of claim 29, further comprising repeating steps (b) through (d) at selected intervals to detect changes in the level of the proton emission in the animal over time.